Dominique Leveque
Family · Indianapolis, INNPI 1285785584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 691 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,293, more than ten times the $400 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 691 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$864
- plus $7K from 36 others
What the payments were for
- Food & beverage$15,28198%
- Education$3592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$699
- QELBREE$402
- INVEGA SUSTENNA$258
- VRAYLAR$249
- COBENFY$240
- UZEDY$237
- Austedo XR$234
- REXULTI$233
- VIVITROL$213
- WATCHMAN Access System$169
- BRIXADI$144
- Mavyret$132
- INGREZZA$128
- INVEGA TRINZA$127
- INVEGA$127
- XCOPRI$121
- AUSTEDO$120
- Fanapt$119
- RELISTOR$117
- Epidiolex$115
How this compares
$15,639 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,035 |
| Modafinil | 11 | $400 |
Paid to pharmacies, not to this prescriber.
Other family in Indianapolis
- Tina SizemoreIndianapolis$888K
- Marla MosesIndianapolis$142K
- Leslye FisherIndianapolis$73K
- Alicia WettrickIndianapolis$72K
- Christine BaltIndianapolis$30K
- Kathryn KennedyIndianapolis$29K
- Andrea RandallIndianapolis$27K
- Deidre ArmsIndianapolis$26K
- Carrie GravesIndianapolis$16K
- Gina DavisIndianapolis$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.